

No.: 11/TTr-HĐQT-IMP

Cao Lanh city, April 1st, 2022

STATEMENT
Operating expenses of the Board of Directors and the Supervisory Board

Respectfully submit to: The General Meeting of Shareholders

In pursuant to Article 25; Clause 4 of Article 33 of the Charter of Imexpharm Corporation regulating on remuneration and expenditures of the Board of Directors and Supervisory Board;

In pursuant to Resolution No: 03/NQ-HĐQT-IMEX of the Board of Director on March 17 2022;

We would like to submit the remuneration and expenditures of the Board of Directors and Supervisory Board in 2022 to the General Meeting of Shareholders for consideration and approval as followings:

1. Renumeration, expenditures for the Board of Directors and Supervisory Board: distributed ratio is 2% of profit before tax and actual paid expense to the BOD and SB.

2. Bonus once the Company achieves the profit plan:

– Bonuses for the Board of Directors and Supervisory Board at the rate of 1% of profit after tax when the Company achieves the profit target

– If the actual profit is higher than the planned profit, the Board of Directors and Supervisory Board will receive 5% of the profit surplus, which equals to the outcome of actual profit deducted by planned profit.

We kindly present to the General Meeting of Shareholders to consider and approve.

Receiver:

- As stated above
- Archive

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN

NGUYEN QUOC DINH